"Study Reveals Shocking Disparity in Cost of Diabetes Drugs"

A new study suggests that pharmaceutical companies are pricing diabetes medicines, including modern insulin pens and GLP-1 receptor agonists, at nearly 400 times the level necessary to make a profit. The study found that these drugs could be sold at a profit for as little as $0.89 a month, but are currently priced between $38.21 and $353.74. The research, published by Médecins Sans Frontières (MSF), highlights the unaffordability of these drugs in many parts of the world, despite rising rates of diabetes. The study calls for pharmaceutical companies to prioritize affordability and access to these life-saving medications, particularly in low and middle-income countries.